InsiderSignalSign in

← Insider buys

SDGR

Schrödinger, Inc. · Healthcare

Insiders sold $2.0M of Schrödinger, Inc. in the last 12 months and bought none

$0Bought, 12 mo

$2.0MSold, 12 mo

$2.0BMarket cap

SDGR over the last year

No insider buys filed in this year

SDGR after insider buys

3 months after each buy, from the first price a copier could get.

No buys have 3 months of prices yet. A record shows here at 3.

Every filing

136 insider filings since 2020, newest first

Karen Akinsanya · Insider

$928K−31.1%Sep 21

Ramy Farid · President and CEO

$1.1M−18.0%Apr 17

Ramy Farid · President and CEO

$47K−1.0%Mar 6

Margaret Dugan · Chief Medical Officer

$27K−10.0%Oct 16

Geoffrey Craig Porges · EVP and CFO

$87K−37.0%Mar 5

Robert Lorne Abel · Insider

$33K−11.0%Feb 13

Kenneth Patrick Lorton · EVP, CTO, COO, Software

$25K−2.0%Feb 13

Kenneth Patrick Lorton · EVP and CTO

$401K−21.0%Aug 10

Yvonne Tran · EVP, CLO and CPO

$602K−49.0%Jul 3

Yvonne Tran · EVP, CLO and CPO

$844K−64.0%May 24

Kenneth Patrick Lorton · EVP and CTO

$401K−17.0%May 24

Nancy Thornberry · Director

$520K−100.0%May 23

Yvonne Tran · EVP and General Counsel

$681K−83.0%Feb 3

Ramy Farid · President and CEO

$1.2M−27.0%Jan 5

Nancy Thornberry · Director

$173K−100.0%Aug 12

Robert Lorne Abel · Insider

$566K−100.0%Dec 14

Karen Akinsanya · Insider

$78K−100.0%Oct 19

Karen Akinsanya · Insider

$85K−100.0%Sep 16

Robert Lorne Abel · Insider

$963K−100.0%Sep 14

Joel Lebowitz · EVP and CFO

$360K−100.0%Sep 3

Karen Akinsanya · Insider

$2.2M−100.0%Aug 17

Yvonne Tran · EVP and General Counsel

$818K−70.0%Aug 4

David E Shaw · 10% owner

$4.3M−1.0%Jul 19

David E Shaw · 10% owner

$5.9M−1.0%Jul 16

Joel Lebowitz · EVP and CFO

$379K−100.0%Jul 16

David E Shaw · 10% owner

$7.5M−2.0%Jul 14

David E Shaw · 10% owner

$4.2M−1.0%Jul 9

David E Shaw · 10% owner

$4.3M−1.0%Jul 7

David E Shaw · 10% owner

$4.6M−1.0%Jul 2

David E Shaw · 10% owner

$9.4M−2.0%Jun 30

David E Shaw · 10% owner

$23.3M−4.0%Jun 25

David E Shaw · 10% owner

$14.0M−3.0%Jun 23

Robert Lorne Abel · Insider

$1.2M−100.0%Jun 22

David E Shaw · 10% owner

$12.4M−2.0%Jun 21

David E Shaw · 10% owner

$10.6M−2.0%Jun 16

Joel Lebowitz · EVP and CFO

$431K−100.0%Jun 15

Rosana Kapeller-Libermann · Director

$75K−100.0%Jun 9

Karen Akinsanya · Insider

$1.3M−100.0%Jun 9

David E Shaw · 10% owner

$5.0M−1.0%May 26

David E Shaw · 10% owner

$5.0M−1.0%May 20

Joel Lebowitz · EVP and CFO

$359K−100.0%May 19

David E Shaw · 10% owner

$4.5M−1.0%May 14

Robert Lorne Abel · Insider

$1.1M−100.0%May 7

David E Shaw · 10% owner

$6.2M−1.0%May 6

David E Shaw · 10% owner

$7.8M−1.0%Apr 29

Charles Ardai · 10% owner

$866K−100.0%Apr 26

David E Shaw · 10% owner

$6.5M−1.0%Apr 21

David E Shaw · 10% owner

$9.3M−1.0%Apr 15

Joel Lebowitz · EVP and CFO

$437K−100.0%Apr 15

David E Shaw · 10% owner

$8.1M−1.0%Apr 9

About Schrödinger, Inc.

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. It has a research collaboration and license agreement with Novartis Pharma AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.

Filings come from SEC EDGAR and prices from daily closes. Not investment advice.